Detection of unknown primary neuroendocrine tumors (CUP-NET) using 68Ga DOTA-NOC receptor PET/CT

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 4599-4599
Author(s):  
D. Hörsch ◽  
V. Prasad ◽  
V. Ambrosini ◽  
M. Hommann ◽  
S. Fanti ◽  
...  
Keyword(s):  
Neuroendocrine Tumours ◽  
Primary Tumour ◽  
Unknown Primary ◽  
Low Grade ◽  
Pet Ct ◽  
Pancreatic Net ◽  
The Mean ◽  
Standardised Uptake Values ◽  
F 33

4599 Background: This bi-centric study aimed at determining the role of receptor PET/CT using 68Ga-DOTA-NOC in the detection of undiagnosed primary sites of neuroendocrine tumours (NETs). Methods: Overall 59 patients (M: F 33:26, age 65±9 yr) with documented NET and unknown primary, were enrolled. PET/CT was performed after injection of approximately 100 MBq (46–260 MBq) of 68Ga-DOTA-NOC. The maximum standardised uptake values (SUVmax) were calculated and compared with SUVmax in known pancreatic NET (pNET) and ileum / jejunum / duodenum (SI-NET). The results of PET/CT were also correlated with CT alone. Results: In 35/59 (59%) of patients, 68Ga-DOTA-NOC PET/CT localised the site of the primary: ileum/jejunum (14), pancreas (16), rectum (2), lungs (2) and paraganglioma (1). CT alone (on retrospective analyses) confirmed the findings in 12/59 (20%) patients. The mean SUVmax of identified previously unknown pNET and SI-Net were 18.6 ± 9.8 (range 7.8–34.8) and 9.1± 6.0 (range 4.2–27.8), respectively. SUVmax in patients with previously known pNET and SI-NET were 26.1± 14.5 (range 8.7–42.4) and 11.3±3.7 (range 5.6- 17.9). The SUVmax of the unknown pNET and SI-NET were significantly lower (p< 0.05) as compared to the ones with known primary tumour sites. 19% of the patients had high grade, and 81% low grade NET. In 4/59 patients the primary tumour was subsequently resected (2 pancretic, one ileal and one rectal tumour). Conclusions: Our data indicate that 68Ga- DOTA-NOC PET/CT is highly superior to 111In Octreoscan (17% detection rate for CUP according to literature) and can play a major role in the management of patients with CUP-NET. No significant financial relationships to disclose.

Primary versus secondary nature of mesenteric neuroendocrine tumours

2021 ◽  
Vol 14 (2) ◽  
pp. e239217
Author(s):  
Ariel Park ◽  
Alicia Martin ◽  
Ramos Carlos ◽  
Vladimir Neychev
Keyword(s):  
Neuroendocrine Tumours ◽  
Single Photon ◽  
Primary Tumour ◽  
Photon Emission ◽  
The Body ◽  
Neuroendocrine Cells ◽  
Unknown Primary ◽  
Emission Computed Tomography ◽  
Unknown Primary Tumour ◽  
Pet Ct

Neuroendocrine tumours (NETs) are rare group of malignancy that originate from neuroendocrine cells present throughout the body. Most patients with NET first present with symptoms associated with metastasis, and up to 20% of patients have unknown primary site of tumour. Most common metastatic sites for small intestine NETs (SI-NETs) are the locoregional lymph nodes and liver. Although mesenteric metastasis through direct extension or lymphatic spread from SI-NETs is common, mesenteric extranodal involvement is extremely rare, and its biology and primary versus secondary nature are not well understood. Due to their small size and location, SI-NETs are frequently undetected on anatomical imaging or indium-111-pentetreotide single-photon emission computed tomography/CT (Octreoscan) and are difficult to be found via endoscopy. Gallium-68-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-octreotate positron emission tomography (68Ga-DOTATATE PET)/CT has been increasingly used for accurate staging, unknown primary tumour site localisation and appropriate management planning. We present a case of an incidentally found mesenteric NET with occult SI-NETs localised preoperatively by 68Ga-DOTATATE PET/CT.

Detection rate of unknown primary tumour by using somatostatin receptor PET/CT in patients with metastatic neuroendocrine tumours: a meta-analysis

Endocrine ◽  
2019 ◽  
Vol 64 (3) ◽  
pp. 456-468 ◽  
Author(s):  
Sara De Dosso ◽  
Giorgio Treglia ◽  
Mariarosa Pascale ◽  
Adriana Tamburello ◽  
Prasanna Santhanam ◽  
...  
Keyword(s):  
Detection Rate ◽  
Neuroendocrine Tumours ◽  
Meta Analysis ◽  
Primary Tumour ◽  
Somatostatin Receptor ◽  
Unknown Primary ◽  
Unknown Primary Tumour ◽  
Pet Ct

scholarly journals The Usefulness of PET/CT In Detecting and Managing Cancers With Unknown Primary Site Depends on Histological Subtype

2021 ◽  
Author(s):  
Ella Nissan ◽  
Uri Amit ◽  
Leo Baron ◽  
Amit Zabatani ◽  
Damian Urban ◽  
...  
Keyword(s):  
Primary Site ◽  
Unknown Primary ◽  
Histological Subtype ◽  
Unknown Primary Site ◽  
Primary Tumors ◽  
Poorly Differentiated Carcinoma ◽  
Pet Ct ◽  
Poorly Differentiated ◽  
The Mean

Abstract Introduction: We assessed the role of PET/CT in identifying and managing cancer of unknown primary site (CUP). Methods: We reviewed 64 patients' PET/CT scans with CUP performed during 2012–2019. Results: The median age was 65 years. Of 138-FDG-avid lesions, the mean SUVmax was10.6±6.0. Primary tumors (PT) were detected in 28(44%) patients. Detection was positive in only one(10%) patient with squamous cell carcinoma (SCC) histology, compared to 4/14(29%) with poorly differentiated carcinoma, 4/9(44%) with adenocarcinoma, 18/30(60%) of those for whom the origin could be presumed (p= 0.034 for SCC compared to other histologies). The mean age, mean SUVmax, and the distribution of organ involvement were similar between patients with and without discovered PTs, and also between patients with SCC and with the other histologies combined. However, those with SCC were less likely than the others to present with multi-lesion involvement, p<0.001. PET/CT interpretations apparently affected treatment of 8/28(29%) patients with PT detected and in none of the 35 whose PT was not discovered, p<0.001. Conclusion: PET/CT detected PT in almost half of CUP. However, it did not appear beneficial in those with SCC histology. PET/CT showed limited overall value in guiding clinical management but benefited a subgroup with discovered PT.

Role of 68Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours

2011 ◽  
Vol 21 (11) ◽  
pp. 2408-2416 ◽  
Author(s):  
Rakesh Kumar ◽  
Punit Sharma ◽  
Pramod Garg ◽  
Sellam Karunanithi ◽  
Niraj Naswa ◽  
...  
Keyword(s):  
Neuroendocrine Tumours ◽  
Pet Ct ◽  
Pancreatic Neuroendocrine Tumours

scholarly journals EVALUATING THE ROLE OF FDG PET-CT SCAN AS A SOLE IMAGING MODALITY IN THE MANAGEMENT OF MUO NECK

2020 ◽  
pp. 39-41
Author(s):  
Krishnappa Krishnappa ◽  
Krishna Prasad ◽  
Shruti Satish ◽  
Murali R Nadig
Keyword(s):  
Ct Scan ◽  
Predictive Value ◽  
Fdg Pet ◽  
Imaging Modality ◽  
False Negative ◽  
Unknown Primary ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Pet Ct Scan

Aim:to study the role of PET- CT SCAN as a single imaging modality in the diagnosis of MUO neck. methodology: retrospective study analysis of 51 cases of clinical unknown primary with cervical metastasis . RESULTS: FDG PET CT tracer uptake was detected in 24/51. true positive in 18 cases out of 24,false positive in 6 cases, false negative in 2 cases with sensitivity of 90%, specificity of 82%,positive predictive value of 75%,negative predictive value of 93% and accuracy of 84.91%. conclusion: FDG PET CT can be used as a sole imaging modality in the diagnosis of MUO neck.it is complimentary to endoscopy.

scholarly journals Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours

2013 ◽  
Vol 40 (6) ◽  
pp. 881-888 ◽  
Author(s):  
Stefano Severi ◽  
Oriana Nanni ◽  
Lisa Bodei ◽  
Maddalena Sansovini ◽  
Annarita Ianniello ◽  
...  
Keyword(s):  
Neuroendocrine Tumours ◽  
18Fdg Pet ◽  
Pet Ct

A Stepwise Approach to Identify the Clinical Role of 18F-FDG PET/CT in Patients With Suspicious Bone Metastasis From an Unknown Primary Site

2019 ◽  
Vol 44 (9) ◽  
pp. e524-e525 ◽  
Author(s):  
Md. Sunny Anam Chowdhury ◽  
Subin Jeon ◽  
Hee-Seung Bom ◽  
Jung-Joon Min ◽  
Seong Young Kwon
Keyword(s):  
Bone Metastasis ◽  
Primary Site ◽  
Unknown Primary ◽  
Unknown Primary Site ◽  
Clinical Role ◽  
Stepwise Approach ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals 18-FDG PET ANALYSYS FOR DEMENTIA DIAGNOSIS- BASELINE RESULTS FROM A REFERENCE CENTER IN RECIFE, BRAZIL

2021 ◽  
Author(s):  
Júlia Xavier Ramos ◽  
Bruno Zacarias ◽  
Breno Barbosa ◽  
Simone Brandão
Keyword(s):  
Differential Diagnosis ◽  
Lewy Bodies ◽  
Diagnostic Uncertainty ◽  
Medical Evaluation ◽  
Pet Ct ◽  
Diagnosis Of Dementia ◽  
Diagnostic Hypothesis ◽  
The Mean ◽  
Near Future

Background: Positrons emission tomography associated with computed tomography- PET/CT using the 18 F-fluorodeoxyglucose is a well-established exam for the medical evaluation of dementia, mainly helping in differential diagnosis to determine the specific type of dementia. Objectives: To describe the role of the PET/CT in the differential diagnosis of dementia in patients. Methods: a single-center, descriptive and records-based analysis of patients with Dementia evaluated in a clinic of Neurology at Recife and referred to PET/ CT due to diagnosis uncertainty, between 2020-2021. Results: 29 patients were included. The mean age was 65 years-old and 62% were female. Alzheimer’s dementia was the main diagnostic hypothesis (41.3%). PET/CT was suggestive of Alzheimer’s in 24%, Frontotemporal dementia in 21% and Lewy Bodies Dementia in 17% of patients. PET/CT results disagreed from clinical hypothesis in 21% o and in 10% it was inconclusive. In 38% it corroborated the clinical suspicion. Conclusions: in this sample the use of PET/CT FDG contributed to improve diagnostic accuracy in a significant subset of patients, mostly in the scenery of diagnostic uncertainty or atypical syndromes such as earlyonset dementias. A larger sample size and the continuation of this research will give us more information in the near future.

Tumor-to-normal tissue (T/N) dosimetry ratios role in assessment of 90Y selective internal radiation therapy (SIRT)

2021 ◽  
Author(s):  
Karin Knešaurek ◽  
Ricardo Bello Martinez ◽  
Munir Ghesani
Keyword(s):  
Normal Tissue ◽  
Complete Response ◽  
Volume Effect ◽  
Locoregional Therapy ◽  
Dose Ratio ◽  
Pet Ct ◽  
Progression Of Disease ◽  
N Dose ◽  
The Mean

Objective: The purpose of our work is to assess the role of tumor-to-normal tissue (T/N) dosimetry ratios for predicting response in patients undergoing locoregional therapy to the liver with 90Y microspheres. Methods: 39 patients (seven femal:32 male, mean age 68.3 ± 7.6y), underwent PET/CT imaging after treatment with 90Y microspheres. For attenuation correction and localization of the 90Y microspheres, the low dose, non-diagnostic CT images from PET/CT were used. The acquisition took 15 min and the reconstruction matrix size was 200 × 200×75 mm and voxel size of 4.07 × 4.07×3.00 mm. For dosimetry calculations the local deposition method with known activity of 90Y was used. For each patient, regions-of-interest (ROIs) for tumor(s) and whole liver were manually created; the normal tissue ROI was created automatically. mRECIST criteria on MRI done at a month post treatment and subsequently every three months after90Y treatment, were used to assess response. Results: For 39 patients, the mean liver, tumor and normal tissue doses (mean ± SD) were, 55.17 ± 26.04 Gy, 911.87 ± 866.54 Gy and 47.79 ± 20.47 Gy respectively. Among these patients, 31 (79%) showed complete response (CR) and 8 (21%) showed progression of disease (PD). For patients with CR, the mean T/N dose ratio obtained was 24.91 (range 3.09–80.12) and for patients with PD, the mean T/N dose ratio was significantly lower, at 6.69 (range 0.36–14.75). Conclusion: Our data shows that patients with CR have a statistically higher T/N dose ratio than those with PD. Because, the number of PD cases was limited and partial volume effect was not considered, further investigation is warranted. Advances in knowledge: Tumor-to-normal tissue dosimetry ratios can be used for assessing response in patients undergoing locoregional therapy to the liver with 90Y microspheres.

Sign in / Sign up

Export Citation Format

Share Document